INTRODUCTION
Komipharm information
NAME OF COMPANY Komipharm International Co., Ltd.
REPRESENTATIVES Yong-Jin, Yang, Seong-cheol, Moon
FOUNDATION September 21, 1972
CAPITAL 6,418,587,600 won.
BUSINESS CATEGORY - Manufacturing: veterinary biological (vaccines), veterinary pharmaceuticals (medicine, disinfectant and e.t.c.), Bio-fertilizer
- Service: Clinical pathological experiment, test, analysis
MAJOR PRODUCT Veterinary product [vaccine, medicine, disinfectant, and e.t.c.]
FORMS OF ENTERPRISE Small & Medium Business (Under Article 2 of The Minor Enterprise Act)
LOCATION The Head Office & First Plant
- 17, Gyeongje-Ro, Siheung-Si, Gyeonggi-Do, South Korea
TSecond Plant
- 235-24, Chusa-Ro, Sinam-Myeon, Yesan-Gun, Chungcheongnam-Do, South Korea
Third plant
- 291, Osonggarak-Ro, Osong-Eup, Cheongwon-Gun, Chungcheonbuk-Do, South Korea
REGISTRATION IN KOSDAQ
[Commencement date of sales]
October 30, 2001
website www.komipharm.com
Related Company
United States

Komipharm Internationall
America, Inc.

  • Representative : Yong-Jin, Yang
  • Capital : $200,000
  • Business category : Supporting KOMINOX development business in both domestic and foreign countries
  • Investment Date : 2005.05.20
  • Investment Classification : subsidiary company
  • Contractual relations : Local subsidiary
  • Compostion : komipharm international co.,Ltd. (100%)
  • Capital composition ratio : 100.00%
United States

Kominox, Inc.
 

  • Representative : Joseph E.Sarachek
  • Capital : $4,500,000
  • Business category : Extended clinical trial, sales approval, and investment promotion of KOMINOX, in all over the world, including U.S.A.
  • Investment Date : 2005.11.29
  • Investment Date : Investment company
  • Contractual relations : Technology transfer royalty dividend
  • Compostion : Consortium between Sinclaire Fund LLC. And Pacific Accomodators Inc (57%) and Komipharm International Co., Ltd.(40%)
Australia

Komipharm International
Australia PTY, LTD.

  • Representative : Yong-Jin, Yang
  • Capital : AUD100,000
  • Business category : Phamaceutical Sales
  • Investment Date : 2015.03.04
  • Investment Classification : subsidiary company
  • Contractual relations : Local subsidiary
  • Compostion : komipharm international co.,Ltd. (100%)
  • Capital composition ratio : 100.00%